Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Labiotech growth media biotech

News and Trends 23 Jun 2016

How did we grow from 0 to 40,000 Monthly Visitors in 18 Months?

The first 18 months of our startup have been a marathon for us, where each new visitor was like one more kilometer to conquer. Growing a digital media is not an easy task, especially if you want to build a good reputation based on the quality of your content. In this article, I share the […]

June 23, 2016 - 7 minutesmins - By Joachim Eeckhout

Sao Paulo Stock Exchange

News and Trends 23 Jun 2016

Cellectis gets paid for a first Milestone, Investors are pleased

After successfully ‘saving’ two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its lead candidate UCART-19. It’s once again a success for the French biotech company! As it announced on Monday, the first patient has been treated in […]

June 23, 2016 - 2 minutesmins - By Jerome Topsent

median microsoft big data oncology

News and Trends 22 Jun 2016

What is Microsoft doing with this French Precision Medicine Biotech?

Median Technologies is partnering up with software giant Microsoft to integrate big data into its oncology imaging systems – and deliver Precision Medicine from the cloud. Medical imaging is an important part of the rise of digital medicine. Cool projects in the field include the aortic graft simulation of EVARplanning (one of the startups at Italian incubator […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr cas9 clinical trial t cell therapy

News and Trends 22 Jun 2016

World’s first CRISPR Clinical trial has just been Approved!

CRISPR has received a regulatory green light in what could be the first clinical trial with the “scientific discovery of the century”. It’ll be used to improve cancer cell therapies. CRISPR has already revolutionized biotech, quickly overtaking the field of gene editing. It also has immense potential in the therapeutic field, so it’s not surprising there’s a lot […]

June 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

f2g fungal infections antifungals aspergillosis

News and Trends 22 Jun 2016

Massive Round: Novel Antifungals get €53M from Top-Notch Investors

F2G has raised €53M to advance its news class of treatments for life-threatening fungal infections, including invasive aspergillosis. The technology has attracted some of the major biotech investors in Europe. Based in Manchester (UK), F2G focuses on developing therapies for invasive fungal infections such as aspergillosis. This type of infections mostly affect patients that are […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

munich biotech leaders

Best in Biotech 22 Jun 2016

11 Biotech Leaders you should meet in Munich

I guess you’ve read some of our tops lately (VCs, Paris, Unicorns). Those were mainly about specific companies or regions. Now, we wanted to try a new format and focus on people instead. For this first edition, we decided to focus on Munich, one of Europe’s top biotech regions. I asked some biotech leaders in Munich […]

June 22, 2016 - 5 minutesmins - By Philip Hemme

ADVERTISEMENT

circassia cat grass allergy toleromune spire

News and Trends 21 Jun 2016

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

Circassia’s pipeline takes a major step back as its therapy for cat allergy gets disappointing results — it had the same effect as the placebo. Stocks promptly sank by 65%. The Oxford-based Circassia has been a major European player in the field of allergy immunotherapies. It made a splash when it raised €267.7M in the London Stock […]

June 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

labiotech refresh microbiome isabelle cremoux

News and Trends 21 Jun 2016

“The Microbiome will be as big as Biotech in 10 Years”

Isabelle de Cremoux, the CEO of Seventure Partners, was at Labiotech Refresh to tell us when and how she fell in love with the microbiome and what the future holds for this exciting field. De Cremoux is the person behind Seventure, one of the top European VCs and the first in the world to focus mainly […]

June 21, 2016 - 4 minutesmins - By Denise Neves Gameiro

astrazeneca asthma copd epigenetic targets

News and Trends 21 Jun 2016

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs for diseases like asthma. After partnering up with genomics elite for a new biobank, AstraZeneca is again preparing to tap into collaborations with academia. This […]

June 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

gmo tobacco artemisinin malaria synbio

News and Trends 20 Jun 2016

GMO Tobacco could Produce cheaper Medicine for Malaria

Researchers from the Max Planck Institute of Molecular Plant Physiology in Potsdam have altered tobacco to produce large yields of artemisinin – the most effective treatment for malaria but still without a cheap and reliable source. Artemisinin is used in the most effective treatments against malaria, the discovery of which was worth a Nobel Prize. […]

June 20, 2016 - 3 minutesmins - By Denise Neves Gameiro

zageno amazon for labs

News and Trends 20 Jun 2016

I tried the Amazon for labs, and it makes life way easier!

Ordering a kit for an experiment could quickly become a nightmare. There are an incredible amount of suppliers out there who are selling similar products that could greatly vary in price and quality. Finding a neutral review on these products is also quite hard as all available references tend to be made by suppliers themselves. Have […]

June 20, 2016 - 4 minutesmins - By Joachim Eeckhout

curetis blood infection diagnostic pathogen resistance

News and Trends 20 Jun 2016

This Sepsis Detection Test saves 24h for Faster Treatment

Curetis has received great results for its diagnostic kit. This new technology to detect sepsis is delivering the same results as standard tests, but it’s faster by 24 hours – critical time to deal with life-threatening infections. Based in Stuttgart (Germany), Curetis was the only German biotech to do an IPO in 2015. It did so with a bang, […]

June 20, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT